Table 2: Distribution of ADMA, reactant of acute phase and other laboratory variables in patients with RA and healthy control group.

Ra not treated group
no. 35
Value (  ± SD)
RAsero−
no. 18
Value (  ± SD)
RAsero+
no. 17
Value (  ± SD)
Control healthy group
no. 35
Value (  ± SD)
Positive/negativePositive/negativePositive/negativePositive/negative

ADMA
+>0.75 μmol/L
20/15
08.10 (±0.75)
(0–210)
7/11
11.22 (±0.72)
(0–110)
13/4
13.16 (±0.40)
(0–210)
4/31
11.75 (±0.22)
(55.20–105.33)

Sedimentation
+≥16
25/10
46.43 (±41.79)
(1.0–110)
11/7
40.70 (±37.63)
(1.0–110)
13/4
51.38 (±37.37)
(1.0–110)
3/32
7.31 (±7.10)
(1.0–31)

Anti CCP2
≥1.26
24/11
1.82 (±0.71)
(0.91–2.0)
12/6
1.45 (±0.48)
(0.91–1.5)
11/6
1.76 (±0.80)
(0.91–1.9)
1/34
0.84 (±0.09)
(0.90–1.27)

RF
+≥8 IU/mL
18/17
335.09 (±515.11)
(0.00–512)
0/18
0.00 (±0.00)
(0.00-0.00)
17/0
601.67 (±622.68)
(32–1024)
3/32
11.69 (±40.69)
(0.00–128)

DAS28
+≥3.2
29/6
5.81 (±1.44)
(1.76–6.01)
14/4
5.30 (±1.55)
(1.72–6.01)
16/1
4.01 (±1.29)
(1.39–5.81)
0/35
0.00 (±0.00)
(0.00-0.00)